Bindi Irwin has had her appendix and '51 endometriosis lesions' removed
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Man thanks opticians for picking up rare cancer
A man has thanked his optician for saving his life after spotting he was unknowingly living with a rare type of blood cancer. Robert Campbell went for a routine eye test in January at Flint Optometry, near his home in Wolverhampton, when optometrist Claire Williams became concerned. She noticed a number of haemorrhages at the back of his eyes and he was soon called into New Cross Hospital, where he was told he had lymphoma. Mr Campbell said he had been feeling unwell for a while but multiple blood tests, a colonoscopy and an endoscopy had not detected the cancer, so it was a "shock" to receive the news. "I got a call from a consultant at New Cross saying they wanted to see me now, so I went and he told me I'd got lymphoma," he said. "I am grateful as without Ms Williams picking it up, I don't know where I'd be now, I dread to think." He added that his cancer was now under control after undergoing chemotherapy. Ms Williams said she made an immediate referral to hospital following his eye test. "As I checked the peripheral part of the back of the eyes, I was able to see quite a number of haemorrhages and a third of them were even more unusual and very rarely seen," she said. Peter Rockett, another optometrist at Flint Optometry, said regular eye tests were important as they could detect more than just poor vision. He said: "You can see deep into the body through a convenient window, the pupil. "So it is a great way to assess someone's eye health as well as their general health." Follow BBC Wolverhampton & Black Country on BBC Sounds, Facebook, X and Instagram. More on this story Single mum graduates despite two chronic illnesses Wolves fan takes on stadium abseil in dad's memory 'Don't let the word cancer get you down' 'I am cancer free thanks to new blood treatment'
Yahoo
2 hours ago
- Yahoo
Radiopharm Theranostics Limited (RADX) Receives IND Approval From FDA To Initiate Phase I Therapeutic Clinical Study To Target B7H3 With Betabart (RV-01)
Radiopharm Theranostics Limited (NASDAQ:RADX) is among the 12 Best Australian Stocks to Buy Right Now. The company recently announced receiving Investigational New Drug (IND) approval from the FDA to begin a Phase 1 therapeutic clinical study to target B7H3 with Betabart (RV-01). A well-stocked pharmacy shelf full of the company's pharmaceuticals, nutraceuticals, over-the-counter medications, and health care products. The Lu-177-B7H3 monoclonal antibody is the first in class targeted radiopharmaceutical that is being developed against the 4lg type of B7H3. Radiopharm Theranostics Limited (NASDAQ:RADX) believes it has the potential to become a highly differentiated drug for treating individuals with aggressive solid tumors. The company says it is on track to initiate the first-in-human study during the fourth quarter of this calendar year. Findings from recent preclinical studies have shown that RV-01 exhibits hepatic clearance, which allows the isotope enough time to target tumors, while also potentially reducing adverse effects such as hematological toxicities. Moreover, these monoclonal antibodies are cleared by the liver, unlike peptides and small molecules. This, coupled with the shortened half-life of RV-01, makes this agent stand out compared to other monoclonal antibodies and targeted radiotherapeutics with a renal excretion pathway. Radiopharm Theranostics Limited (NASDAQ:RADX) is an Australia-based clinical-stage radiotherapeutics firm developing innovative radiopharmaceutical products for therapeutic and diagnostic applications in areas of high unmet medical need. While we acknowledge the potential of RADX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Best Large Cap Defense Stocks to Buy According to Analysts and 10 Best Low Priced Defense Stocks to Buy Now. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Incannex Healthcare Inc. (IXHL) Receives Positive Patient-Reported Outcomes For IHL-42X in Obstructive Sleep Apnoea
Incannex Healthcare Inc. (NASDAQ:IXHL) is among the 12 Best Australian Stocks to Buy Right Now. On August 8, the company announced positive new patient-reported outcomes from participants in its RePOSA Phase 2 trial of IHL-42X to treat obstructive sleep apnoea (OSA). A scientist in a lab coat examining a Petri dish containing a biopharmaceutical culture. The new insights were collected through exit interviews, in line with FDA's guidance on Patient-Focused Drug Development (PFDD). The results build on already compelling data to reinforce the potential of IHL-42X to improve sleep quality, cognitive function, and daily life. Incannex Healthcare Inc. (NASDAQ:IXHL) said that 57.6% of the respondents reported an improvement in their OSA, of which 89.5% described it as a meaningful change to their lives. Some of the reported benefits include better sleep quality, reduced sleepiness during the daytime, feeling fresh in the morning, and other cognitive and daily-life improvements. Joel Latham, President and CEO of Incannex Healthcare Inc. (NASDAQ:IXHL) stated the following on the findings: 'Our recent Phase 2 results for IHL-42X exceeded expectations. In some patients, we observed reductions in AHI of up to 83%, which is an extraordinary outcome and a powerful signal of the drug's potential. We believe the findings from the patient exit interviews underscore that these improvements are not just clinical—they are translating into meaningful, positive changes in patients' daily lives. This reinforces our belief that IHL-42X has the potential to significantly shift the treatment paradigm for OSA.' Incannex Healthcare Inc. (NASDAQ:IXHL) is a clinical-stage pharmaceutical company developing medicines to treat chronic conditions, including obstructive sleep apnea, generalized anxiety disorder, and rheumatoid arthritis. While we acknowledge the potential of IXHL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 11 Best Large Cap Defense Stocks to Buy According to Analysts and 10 Best Low Priced Defense Stocks to Buy Now. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
